Blood pressure lowering does not reduce risk of cardiovascular events in patients at intermediate riskBMJ 2016; 353 doi: https://doi.org/10.1136/bmj.i1899 (Published 04 April 2016) Cite this as: BMJ 2016;353:i1899
- Ingrid Torjesen
A major trial on the potential of statins and antihypertensives to reduce cardiovascular events in intermediate risk people has found that blood pressure lowering does not reduce the risk of such events.1
For the Heart Outcomes Prevention Evaluation (HOPE)-3 trial, the results of which have been published in the New England Journal of Medicine, 12 705 intermediate risk patients (men aged at least 55 and women aged at least 60) without cardiovascular disease were randomly assigned to receive cholesterol lowering treatment with rosuvastatin 10 mg a day or placebo. The trial had a 2 x 2 factorial design, so patients …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial